Shukra Pharmaceuticals Limited announced significant board changes following its board meeting held on December 30, 2025. The meeting, which commenced at 6:30 PM and concluded at 7:10 PM, resulted in the appointment of a new Independent Director and the resignation of an existing board member, leading to comprehensive committee reconstitution.

New Director Appointment

The board approved the appointment of Mr. Dinesh Chauhan (DIN: 11456530) as Additional Director (Non-Executive Independent Director) for a three-year term effective December 30, 2025. The appointment is subject to approval by the company's members at the ensuing Annual General Meeting.

Mr. Chauhan brings over 7 years of business management expertise, with demonstrated abilities in overseeing and enhancing organizational operations. His experience includes driving performance, streamlining processes, and fostering productive work environments that support strategic goals and business growth. The company confirmed that Mr. Chauhan is not related to any existing directors on the board and is not debarred from holding directorship by SEBI or any other authority.

Director Resignation

Simultaneously, the board noted the resignation of Ms. Bhoomi Patel (DIN: 08316893) from her position as Independent Director, effective December 30, 2025. Ms. Patel cited personal reasons for her departure in her resignation letter submitted to the board.

With her resignation, Ms. Patel also ceased to be a member of the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee. The company confirmed that she does not hold directorship in any other listed entity and is not a member of any other board committee.

Committee Reconstitution

Following these board changes, the company reconstituted its key committees with Mr. Dinesh Chauhan assuming chairperson roles across all three committees:

All committee members hold Non-Executive Independent Director positions, ensuring compliance with regulatory requirements for board committee composition.

Regulatory Compliance

The announcements were made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted the board meeting outcome to BSE Limited (Scrip Code: 524632), including detailed profiles of the appointed director and resignation letters from the departing director. All necessary statutory and regulatory compliances, including filings with the Registrar of Companies and Stock Exchange, will be completed as required under the Companies Act, 2013, SEBI (LODR) Regulations, and other applicable laws.

The board changes reflect the company's commitment to maintaining strong governance standards while ensuring continuity in its operations and strategic direction.

Shukra Pharmaceuticals Limited, a prominent player in the pharmaceutical industry, has announced a strategic move to broaden its presence in the healthcare and wellness sector. The company has incorporated a new subsidiary, Shukra Robotics Private Limited, marking its entry into the realm of medical technology and robotics.

Key Details of the Incorporation

Business Focus

Shukra Robotics Private Limited is set to operate in several key areas within the healthcare sector:

1. Hospital activities
2. Other human health activities (including independent ambulance services)
3. Manufacture of medical and dental instruments

This diversification aligns with Shukra Pharmaceuticals' strategic objective to expand its footprint in the healthcare and wellness industry, potentially leveraging technological advancements in medical robotics.

Corporate Structure and Compliance

The newly formed subsidiary will be classified as a related party to Shukra Pharmaceuticals Limited. This incorporation has been duly reported to the BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency and regulatory compliance.

Industry Implications

This move by Shukra Pharmaceuticals indicates a growing trend of pharmaceutical companies venturing into healthcare technology. By establishing a presence in medical robotics and instrumentation, the company may be positioning itself to capitalize on the increasing integration of technology in healthcare delivery and management.

The incorporation of Shukra Robotics Private Limited represents a significant step for Shukra Pharmaceuticals, potentially opening new avenues for growth and innovation in the evolving healthcare landscape. Stakeholders will likely be watching closely to see how this strategic expansion unfolds and impacts the company's future operations and market position.